Hospitals are trusted institutions of care, but they also generate wastewater containing a complex mixture of pharmaceutical residues, disinfectants, diagnostic agents, pathogens, and antimicrobial-resistant microorganisms. Among these contaminants, pharmaceuticals are increasingly recognized as a significant environmental concern because of their persistence, biological activity, and the challenges associated with their removal. And yet, across most of Europe, this wastewater is treated no differently from domestic sewage.
As Europe advances towards a climate-neutral, resource-efficient, and pollution-free future, reducing pharmaceutical emissions from hospital wastewater has become a key sustainability priority. It is not only about improving water quality, but also about protecting ecosystems and public health by supporting the objectives of the European Green Deal, and ensuring that innovative treatment technologies deliver measurable environmental benefits.
Pharmaceuticals: A Unique Environmental Challenge
Medicines are designed to interact with biological systems at very low concentrations, which is what makes them clinically effective and environmentally challenging. After administration, many active pharmaceutical ingredients are excreted unchanged or transformed into metabolites that remain biologically active. These compounds enter hospital wastewater at concentrations typically far exceeding those found in municipal wastewater, and they arrive in forms that conventional treatment infrastructure often cannot completely remove.
Hospital wastewater is a particular hotspot. It concentrates specialised drugs such as cytostatic compounds used in cancer treatment, iodinated and gadolinium-based contrast agents used in diagnostic imaging, antibiotics administered at clinical doses, alongside resistant microorganisms and resistance genes. As a result, pharmaceutical residues can be released into rivers, lakes, groundwater, and coastal waters. Scientific evidence consistently shows that these substances can alter aquatic ecosystems, disrupt endocrine systems, contribute to biodiversity loss, and propagate antibiotic resistance along waterways, even at trace concentrations. The long-term cumulative effects remain incompletely understood, which itself represents a precautionary reason to act.
Why Are These Contaminants So Difficult to Remove?
Conventional wastewater treatment plants were designed primarily to remove organic matter, nutrients, and suspended solids. Many pharmaceutical compounds, however, are highly stable, water-soluble, and resistant to biological degradation – properties that allow them to pass through standard treatment largely intact.
Advanced treatment technologies exist such as ozonation, activated carbon adsorption, advanced oxidation processes, membrane filtration, or innovative hybrid systems. However, selecting the most appropriate approach is not simply a matter of identifying the highest removal rate. Hospital environments present specific constraints such as limited space and infrastructure, strict operational requirements, infection prevention protocols, and the need for solutions that can be integrated into existing facilities without prohibitive disruption. A truly effective solution must be compact, modular, and adaptable to diverse hospital settings across different European countries.
Sustainability Means Looking Beyond Treatment Performance
A treatment technology that removes pharmaceuticals effectively may also consume significant amounts of energy, require large quantities of chemicals, generating secondary waste streams or depending on non-circular materials and consumables is not a sustainable solution. It may solve one environmental problem while creating others.
Environmental performance assessment provides a broader perspective by evaluating both the technical and functional performance of the technology and the impacts associated with a treatment solution throughout its entire lifecycle. Important considerations include energy consumption, resources consumption, emissions to the environment including GHG emissions, material use, waste generation, operational requirements, and infrastructure needs.
Lifecycle thinking is central to this assessment. Lifecycle Assessment (LCA) provides a methodology for evaluating the environmental impacts of a treatment solution from manufacturing and installation through to operation, maintenance, and end-of-life management. This prevents burden-shifting, the risk that a technology reduces pharmaceutical pollution in waterways while creating equivalent or greater impacts upstream in its supply chain or downstream in its waste. In addition, Environmental Technology Verification (ETV), conducted under ISO 14034 by an accredited verification body, provides independent, standardised confirmation that the environmental improvements claimed by a technology are real, measurable, and reproducible under defined operating conditions.
Affordability and Social Sustainability
Advanced treatment is meaningful if hospitals can actually afford to implement it. Lifecycle cost, covering both upfront capital investment and ongoing operational expenditure, matters more than purchase price alone, and transparent cost data is essential for making the case to hospital management and policymakers alike. What is affordable in a well-resourced northern European hospital may be out of reach for a public institution in a more income-constrained healthcare system. Beyond cost, the social dimension of implementation matters. Healthcare workers are already operating under significant pressure, and any treatment solution that adds complex operational demands, requires specialist expertise, or creates new occupational health risks compounds that burden. Sustainable solutions must be designed with the people who run them in mind.
Finally, the materials, chemicals, and components that make up a treatment system carry their own environmental and social footprints. Supply chain responsibility, including labour standards and resource extraction impacts, is part of what it means for a solution to be sustainable.
Supporting One Health and the Regulatory Horizon
Pharmaceutical pollution is closely linked to one of today’s most pressing global challenges: antimicrobial resistance (AMR). Antibiotic residues discharged into wastewater can contribute to the selection and spread of resistant bacteria and resistance genes, creating risks for humans, animals, and ecosystems alike.
This highlights the importance of the One Health approach, which recognises the close interconnection between human health, animal health, and environmental health. Effective treatment of hospital wastewater helps reduce environmental exposure to pharmaceuticals and resistant microorganisms, contributing to healthier ecosystems and communities. The European Green Deal, the Zero Pollution Action Plan, the Chemicals Strategy for Sustainability, the revised Urban Waste Water Treatment Directive, and the EU’s Pharmaceutical Strategy all agree that pharmaceutical pollution must be reduced. Reducing pollution, improving resource efficiency, minimizing lifecycle impacts, and promoting sustainable innovation are all essential components of Europe’s pathway towards a greener and more resilient future.